Bisoprolol in idiopathic pulmonary arterial hypertension: An explorative study

European Respiratory Journal

Volumn 48, Issue 3, 2016, Pages 787-796

  Van Campen, Jasmijn S J A ^a,b   De Boer, Karin ^b   Van De Veerdonk, Mariëlle C ^a,b   Van Der Bruggen, Cathelijne E E ^a   Allaart, Cor P ^b   Raijmakers, Pieter G ^a   Heymans, Martijn W ^a   Marcus, J Tim ^a   Harms, Hendrik J ^a   Handoko, M Louis ^b   De Man, Frances S ^a,b   Noordegraaf, Anton Vonk ^a   Bogaard, Harm Jan ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BISOPROLOL; DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ARTICLE; BACTERIAL INFECTION; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; EXERCISE; FATIGUE; HEART INDEX; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART RATE; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE EJECTION FRACTION; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; ADULT; AGED; COMPLICATION; DOUBLE BLIND PROCEDURE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE FUNCTION; HEMODYNAMICS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDY; WALKING;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BISOPROLOL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EXERCISE; FAMILIAL PRIMARY PULMONARY HYPERTENSION; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; VENTRICULAR FUNCTION, LEFT; VENTRICULAR FUNCTION, RIGHT; WALKING;

EID: 84986218444     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00090-2016     Document Type: Article

References (37)

1. Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012; 142: 448-456.
2. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
3. Ling Y, Johnson MK, Kiely DG, et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med 2012; 186: 790-796.
4. van de Veerdonk MC, Kind T, Marcus JT, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 2011; 58: 2511-2519.
5. Lau EMT, Tamura Y, McGoon MD, et al. The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress. Eur Respir J 2015; 46: 879-882.
6. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147-e239.
7. Provencher S, Herve P, Jais X, et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006; 130: 120-126.
8. Peacock A, Ross K. Pulmonary hypertension: a contraindication to the use of adrenoceptor blocking agents. Thorax 2010; 65: 454-455.
9. Bandyopadhyay D, Bajaj NS, Zein J, et al. Outcomes of blocker use in pulmonary arterial hypertension: a propensity-matched analysis. Eur Respir J 2015; 46: 750-760.
10. Ciarka A, Doan V, Velez-Roa S, et al. Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 181: 1269-1275.
11. Triposkiadis F, Karayannis G, Giamouzis G, et al. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009; 54: 1747-1762.
12. Bristow MR, Quaife RA. The adrenergic system in pulmonary arterial hypertension: bench to bedside (2013 Grover Conference series). Pulm Circ 2015; 5: 415-423.
13. Ryan JJ, Archer SL. The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res 2014; 115: 176-188.
14. Bogaard HJ, Natarajan R, Mizuno S, et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med 2010; 182: 652-660.
15. de Man FS, Handoko ML, van Ballegoij JJM, et al. Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. Circ Heart Fail 2012; 5: 97-105.
16. Drake JI, Gomez-Arroyo J, Dumur CI, et al. Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension. Physiol Genomics 2013; 45: 449-461.
17. Perros F, Ranchoux B, Izikki M, et al. Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension. J Am Coll Cardiol 2015; 65: 668-680.
18. Bradlow WM, Hughes ML, Keenan NG, et al. Measuring the heart in pulmonary arterial hypertension (PAH): implications for trial study size. J Magn Reson Imaging 2010; 31: 117-124.
19. Wong YY, Raijmakers P, van Campen J, et al. 11C-Acetate clearance as an index of oxygen consumption of the right myocardium in idiopathic pulmonary arterial hypertension: a validation study using 15O-labeled tracers and PET. J Nucl Med 2013; 54: 1258-1262.
20. So PP-S, Davies RA, Chandy G, et al. Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension. Am J Cardiol 2012; 109: 1504-1509.
21. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010-3019.
22. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
23. Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149: 521-530.
24. Thenappan T, Roy SS, Duval S, et al. blocker therapy is not associated with adverse outcomes in patients with pulmonary arterial hypertension: a propensity score analysis. Circ Heart Fail 2014; 7: 903-910.
25. Moretti C, Grosso Marra W, D'Ascenzo F, et al. Beta blocker for patients with pulmonary arterial hypertension: a single center experience. Int J Cardiol 2015; 184: 528-532.
26. Grinnan D, Bogaard HJ, Grizzard J, et al. Treatment of group I pulmonary arterial hypertension with carvedilol is safe. Am J Respir Crit Care Med 2014; 189: 1562-1564.
27. Simon T, Mary-Krause M, Funck-Brentano C, et al. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation 2001; 103: 375-380.
28. Seeland U, Regitz-Zagrosek V. Sex and gender differences in cardiovascular drug therapy. Handb Exp Pharmacol 2012; 214: 211-236.
29. Lehmann LH, Rostosky JS, Buss SJ, et al. Essential role of sympathetic endothelin A receptors for adverse cardiac remodeling. Proc Natl Acad Sci USA 2014; 111: 13499-13504.
30. Beanlands RS, Nahmias C, Gordon E, et al. The effects of ?1-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: a double-blind, placebo-controlled, positron-emission tomography study. Circulation 2000; 102: 2070-2075.
31. Zhang Y, de Peuter OR, Kamphuisen PW, et al. Search for HRV-parameters that detect a sympathetic shift in heart failure patients on blocker treatment. Front Physiol 2013; 4: 81.
32. Fauchier L, Babuty D, Melin A, et al. Heart rate variability in severe right or left heart failure: the role of pulmonary hypertension and resistances. Eur J Heart Fail 2004; 6: 181-185.
33. Xhyheri B, Manfrini O, Mazzolini M, et al. Heart rate variability today. Prog Cardiovasc Dis 2012; 55: 321-331.
34. Kubon C, Mistry NB, Grundvold I, et al. The role of beta-blockers in the treatment of chronic heart failure. Trends Pharmacol Sci 2011; 32: 206-212.
35. Swiston JR, Johnson SR, Granton JT. Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: a systematic review of the literature. Respir Med 2010; 104: 1588-1607.
36. Bengel FM, Ueberfuhr P, Schiepel N, et al. Myocardial efficiency and sympathetic reinnervation after orthotopic heart transplantation: a noninvasive study with positron emission tomography. Circulation 2001; 103: 1881-1886.
37. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996; 94: 2817-2825.